PD-L1基因多态性预测晚期非小细胞肺癌PD-1阻断治疗的生存结局
该回顾性研究在两个独立队列(133例纳武利尤单抗治疗和96例无免疫检查点抑制剂治疗史)中分析PD-L1多态性与生存结局的关联。结果显示PD-L1 rs822339 A/A基因型患者总生存显著优于A/G或G/G基因型(未达到 vs 12.0个月,HR 0.35,95%CI 0.18-0.64,p=0.0008),且为非ICI队列中未观察到此关联。rs1411262 T/T基因型也显示总生存延长。
要点
- PD-L1 rs822339 A/A基因型与纳武利尤单抗治疗晚期NSCLC患者总生存显著延长相关。
- rs822339的生存获益与驱动基因突变状态无关。
- rs1411262 T/T基因型也显示总生存显著延长。
核心结论
- PD-L1多态性与纳武利尤单抗治疗的NSCLC患者有利的总生存相关,可能作为预测生物标志物。
研究设计与样本
- 回顾性分析两个独立队列:133例接受纳武利尤单抗治疗的晚期NSCLC患者和96例无免疫检查点抑制剂治疗史的患者(非ICI队列)。
主要发现
- 在7个研究的单核苷酸多态性中,PD-L1 rs822339和rs1411262与纳武利尤单抗治疗患者的总生存相关。
- rs822339 A/A基因型患者总生存显著长于A/G或G/G基因型(未达到 vs 12.0个月;HR 0.35;95%CI 0.18-0.64;p=0.0008)。
- 无论驱动基因突变状态如何,A/A基因型均观察到相似的生存获益。
- 多因素分析中,体能状态(PS)和PD-L1 rs822339基因型是总生存的独立预后因素。
- 在非ICI队列中,PD-L1 rs822339基因型与总生存无关(HR 0.77;95%CI 0.31-1.70;p=0.55)。
临床怎么用
- PD-L1 rs822339和rs1411262基因型可能有助于筛选从纳武利尤单抗治疗中获益的晚期NSCLC患者,且不受驱动基因状态影响。
局限性
- 回顾性研究设计,样本量有限,需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported that PD-L1 polymorphisms are associated with the efficacy and immune-related adverse events of PD-1 blockade with nivolumab. However, the association between PD-L1 polymorphisms and survival outcomes under PD-1/PD-L1 blockade is still uncertain. Here, we aimed to investigate whether PD-L1 polymorphisms are associated with survival outcomes in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab. METHODS: PD-1/PD-L1 polymorphisms and survival outcomes were retrospectively analysed in two independent cohorts (133 patients treated with nivolumab and 96 patients with no treatment history of an immune checkpoint inhibitor (ICI) (the non-ICI cohort)) with advanced NSCLC. RESULTS: Among the 7 studied single-nucleotide polymorphisms, PD-L1 rs822339 and rs1411262 were associated with overall survival (OS) in patients treated with nivolumab. Patients with the A/A genotype of rs822339 had a significantly longer OS than those with A/G or G/G genotypes (not reached versus 12.0 months; hazard ratio (HR), 0.35; 95% confidence interval (CI), 0.18-0.64; p = 0.0008). A similar survival benefit with the A/A genotype was observed regardless of driver mutation status. In multivariate analysis, performance status (PS) and PD-L1 rs822339 genotype were independent prognostic factors for OS. In the non-ICI cohort, the PD-L1 rs822339 genotype did not correlate with OS (HR, 0.77; 95% CI, 0.31-1.70; p = 0.55). The T/T genotype of rs1411262 also showed a significant prolongation of OS compared to that with the C/T or C/C genotypes in patients treated with nivolumab. CONCLUSIONS: PD-L1 polymorphisms are associated with favourable OS in nivolumab-treated NSCLC patients and may be useful predictive biomarkers, regardless of driver mutation status.
引用
- Yoshida H, Nomizo T, Ozasa H, et al. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade. Eur J Cancer. 2020. PMID: 33385948. doi:10.1016/j.ejca.2020.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。